LT belegger schreef op 6 april 2018 16:37:
[...]
OUTLOOK 2018For the remainder of 2018, the Company expects:
•
Continued growth in revenues from sales of RUCONEST®, mainly driven by the USA and Western Europe operations.• Achievement of
positive quarterly net earnings during the year.
• Continued investment in the
expansion of production of RUCONEST® in order to ensure continuity of supply to the growing markets in the US, Europe and the Rest of the World.
• Investment in
further clinical trial programs for RUCONEST® in acute treatment and prophylaxis of HAE and the development of a small intravenous version and new intramuscular and subcutaneous versions of RUCONEST® as well as research into other routes of administration.
• Investment in clinical trials to explore
additional indications for RUCONEST®.
•
Investment in development of the new pipeline programs in Pompe disease and Fabry’s disease, and other new development opportunities and assets as these occur.
• Increasing marketing activity where this can be profitable for Pharming.
• We will continue to support all our teams and marketing partners in order to enable the maximization of the sales and
distribution potential of RUCONEST® for patients in all territories, as we continue to believe that RUCONEST® represents a fast, effective, reliable and safe therapy option to treat acute angioedema attacks in patients with HAE.